BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 9300223)

  • 1. Autoantibodies to oxidized low density lipoprotein: the relationship to low density lipoprotein fatty acid composition in diabetes.
    Griffin ME; McInerney D; Fraser A; Johnson AH; Collins PB; Owens D; Tomkin GH
    Diabet Med; 1997 Sep; 14(9):741-7. PubMed ID: 9300223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women.
    Dotevall A; Hulthe J; Rosengren A; Wiklund O; Wilhelmsen L
    Clin Sci (Lond); 2001 Nov; 101(5):523-31. PubMed ID: 11672458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation.
    Maggi E; Marchesi E; Ravetta V; Martignoni A; Finardi G; Bellomo G
    J Hypertens; 1995 Jan; 13(1):129-38. PubMed ID: 7759843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus.
    Leinonen JS; Rantalaiho V; Laippala P; Wirta O; Pasternack A; Alho H; Jaakkola O; Ylä-Herttuala S; Koivula T; Lehtimäki T
    Free Radic Res; 1998 Aug; 29(2):137-41. PubMed ID: 9790515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immune response against modified low-density lipoproteins in patients with non-insulin-dependent diabetes mellitus].
    González M; Rojas N; Durán D; Schade A; Campos R; Milos C
    Rev Med Chil; 1997 Aug; 125(8):879-85. PubMed ID: 9567390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationships between serum levels of autoantibodies against oxidized low density lipoproteins, lipid-soluble antioxidants and apolipoprotein B in patients with coronary heart disease.
    Bakalova RA; Hadzhimitova V; Ribarov S
    Gen Physiol Biophys; 2000 Mar; 19(1):103-13. PubMed ID: 10930142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients.
    Girona J; Manzanares JM; Marimón F; Cabré A; Heras M; Guardiola M; Ribalta J; Masana L
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):380-7. PubMed ID: 17904830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Auto antibodies against oxidized low density lipoprotein in severe preeclampsia.
    Jain M; Sawhney H; Aggarwal N; Vashistha K; Majumdhar S
    J Obstet Gynaecol Res; 2004 Jun; 30(3):188-92. PubMed ID: 15210040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
    Tsimikas S; Lau HK; Han KR; Shortal B; Miller ER; Segev A; Curtiss LK; Witztum JL; Strauss BH
    Circulation; 2004 Jun; 109(25):3164-70. PubMed ID: 15184281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody against oxidized low-density lipoprotein predicting myocardial infarction.
    Puurunen M; Mänttäri M; Manninen V; Tenkanen L; Alfthan G; Ehnholm C; Vaarala O; Aho K; Palosuo T
    Arch Intern Med; 1994 Nov; 154(22):2605-9. PubMed ID: 7979858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
    Santos AO; Fonseca FA; Fischer SM; Monteiro CM; Brandão SA; Póvoa RM; Bombig MT; Carvalho AC; Monteiro AM; Ramos E; Gidlund M; Figueiredo Neto AM; Izar MC
    Clin Chim Acta; 2009 Aug; 406(1-2):113-8. PubMed ID: 19523463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.
    Boullier A; Hennuyer N; Tailleux A; Furman C; Duverger N; Caillaud JM; Castro G; Fievet C; Fruchart JC; Duriez P
    Clin Sci (Lond); 2001 Mar; 100(3):343-55. PubMed ID: 11222122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
    Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
    J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies to malondialdehyde-modified low-density lipoprotein in patients with angiographically confirmed coronary artery disease.
    McDowell A; Young IS; Wisdom GB
    J Pharm Pharmacol; 2002 Dec; 54(12):1651-7. PubMed ID: 12542895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidized low-density lipoprotein autoantibodies, chronic infections, and carotid atherosclerosis in a population-based study.
    Mayr M; Kiechl S; Tsimikas S; Miller E; Sheldon J; Willeit J; Witztum JL; Xu Q
    J Am Coll Cardiol; 2006 Jun; 47(12):2436-43. PubMed ID: 16781371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome.
    Romero FI; Atsumi T; Tinahones FJ; Gómez-Zumaquero JM; Amengual O; Khamashta MA; Hughes GR
    Arthritis Rheum; 1999 Dec; 42(12):2606-11. PubMed ID: 10616007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase-positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins.
    Slot MC; Theunissen R; van Paassen P; Damoiseaux JG; Tervaert JW;
    Clin Exp Immunol; 2007 Aug; 149(2):257-64. PubMed ID: 17521320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum antibodies to oxidized low-density lipoprotein and ceroid in chronic periaortitis.
    Parums DV; Brown DL; Mitchinson MJ
    Arch Pathol Lab Med; 1990 Apr; 114(4):383-7. PubMed ID: 2322097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the PRO12ALA polymorphism of the PPAR-gamma2 gene with oxidized low-density lipoprotein and cardiolipin autoantibodies in nondiabetic and type 2 diabetic subjects.
    Niskanen L; Lindi V; Erkkilä A; Sivenius K; Luoma J; Ylä-Herttuala S; Laakso M; Uusitupa MI
    Metabolism; 2003 Feb; 52(2):213-7. PubMed ID: 12601635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-oxidized low-density lipoprotein antibody levels are associated with the development of type 2 diabetes mellitus.
    Garrido-Sánchez L; Cardona F; García-Fuentes E; Rojo-Martínez G; Gómez-Zumaquero JM; Picón MJ; Soriguer F; Tinahones FJ
    Eur J Clin Invest; 2008 Sep; 38(9):615-21. PubMed ID: 18837736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.